[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:histiocytic-sarcoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":28,"states":29},"Histiocytic Sarcoma",3,[7,15,22],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06712810","Q702 for the Treatment of Patients With Hematologic Malignancies",[11],"Phase 1","RECRUITING","2026-08-26T02:16:20.336282Z","2026-05-05T02:43:29.581486Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT04079179","Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders",[19],"Phase 2","2026-08-26T02:16:31.714843Z","2026-05-05T02:43:28.622477Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT05915208","Histiocytic Disorder Follow-up Study",[],"2026-08-26T02:15:50.539717Z","2026-05-13T02:55:06.394598Z",[],[]]